Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,239.20
(
-1.24%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
105.22
(
3.04%
)
Bitcoin
76,229.18
(
-1.48%
)
News Focus
News Focus
Post# of 257454
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122891
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rfj1862 post# 224180

Tuesday, 03/19/2019 12:10:15 PM

Tuesday, March 19, 2019 12:10:15 PM

Post# of 257454
ENTA is a sleeper entrant in the HBV arena. ENTA’s proven drug-discovery expertise in viral/liver diseases gives me confidence that their HBV core inhibitor will be a good one.

Among the new MoAs being tested by the various players are:

• Core-protein inhibition
• Capsid inhibition
• S-antigen inhibition
• RNA degradation

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today